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Abstract The purpose of this investigation was to perform an
evaluation of the prevalence and socioeconomic risk factors
for human cytomegalovirus (HCMV) infections in a cohort of
Polish pregnant women between 2010 and 2011. HCMV-
specific IgG and IgM antibody levels were assayed with
enzyme-linked immunosorbent assay (ELISA) tests in serum
samples collected from 1,250 pregnant women attending out-
patient obstetric clinics and hospitalized at two hospitals in
Lodz. The seroprevalence of anti-HCMV IgG and IgM anti-
bodies was 62.4 and 2.2 %, respectively, and differed signif-
icantly between age-stratified groups (p≤0.05). The highest
IgG prevalence was observed in women above 36 years of age
(76.2 %) and IgM in adolescent women aged 16–20 years
(6.0 %). Of the various socioeconomic factors, age above
36 years, basic and professional education, and offspring were
significantly associated with HCMV IgG prevalence rates
(PRs; 1.89, 1.80, and 1.56, respectively). Financial status,
occupational risk related to contact with children, and trans-
fusions were not related to the prevalence of IgG antibodies.
The IgM prevalence was not associated with any of the
analyzed risk factors. A slightly higher prevalence was ob-
served in women who were transfused in the past, but the
relationship was not significant. The current data have re-
vealed a decrease in HCMV IgG seroprevalence in our region
during recent years (62.4 vs. 76.7 %). Basic and professional
education, as well as bringing up offspring, were determined
as significant risk factors for HCMV infections in Polish
pregnant women [risk ratio (RR) 1.20 and 1.17, respectively],
suggesting that the primary and secondary prophylaxis of
cytomegaly is necessary during pregnancy, even if screening
is not mandatory.
Introduction
Human cytomegalovirus (HCMV) is the most common factor
of intrauterine viral infections, transmitted in urine, blood,
saliva, by breastfeeding, genitourinary tract secretions, feces,
tears, and transplanted organs [1–7]. HCMV infections may
be acquired prenatally, perinatally, or postnatally, and can
cause permanent physical sequelae, with an increased risk of
infant mortality. Congenital infections occur via vertical trans-
mission of the virus by a hematogenous route from infected
pregnant woman to the fetus via the placenta [6]. The inci-
dence rates of viral transmissions from mothers with primary
infections during pregnancy to their fetuses are estimated to be
in the range 30–40%, while in those with recurrent infections,
the range is 0.2–2.2 % [8–12]. The diagnosis of cytomegaly is
based mostly on serological tests during pregnancy. The pri-
mary infection is defined as HCMV IgG seroconversion dur-
ing pregnancy but, in most cases, the distinction between
primary and non-primary maternal cytomegaly is very diffi-
cult, due to the lack of data on the preconception serologic
status. The presence of specific HCMV IgM antibodies and
the low IgG avidity do not always indicate recent primary
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infection [8, 13]. In most cases, systematic ultrasound is not
sensitive enough to detect signs of fetal cytomegaly beside its
most characteristic symptoms, such as microcephaly,
ventriculomegaly, increased periventricular echogenicity, and
calcifications [8, 14].
Congenital HCMV infections during the first trimester of
pregnancy are more likely to cause a severe form of the
disease, but symptomatic cases were also reported, when
transmission occurred in the third trimester of pregnancy
[15]. Approximately 10 to 15 % of in utero infected newborns
demonstrate clinical symptoms observed in various organs
and systems and 85–90% of these children will develop some
degree of psychomotor and mental retardation, including
visual impairment and sensorineural hearing loss [8, 16].
Children born with asymptomatic HCMV infections (85–
90 %) may also acquire cytomegaly-related symptoms,
such as hearing impairment and difficulties in learning
during the first months or, more often, in the first few years
of life [6, 8, 11].
The prevalence of HCMV IgG antibodies varies between
continents and countries, ranging from 40 to 100 % [7, 17,
18]. The prevalence rate of 76.7 % was observed in Polish
pregnant women between the years 1999 and 2009, being one
of the highest in Europe, alongside such countries as Sweden
or Italy (72 and 68 %, respectively) [3, 17, 19]. So far, studies
in different countries have revealed elevated prevalence rates
of congenital HCMV, related to non-white race, increased
sexual activity with multiple partners, age below 25 years,
an increased age of pregnant women, multiparity, preschool
children in the household, and occupational exposure to chil-
dren, as well as lower socioeconomic status (SES) [7, 20–22].
The reported SES risk factors for increased HCMVprevalence
included a lower level of education and lower incomes of
pregnant women [23–26].
In the reported study, we investigated the prevalence of
specific anti-HCMV IgG and IgM antibodies and the socio-
economic risk factors of HCMV infections in a group of
pregnant women from Poland attending outpatient obstetric
clinics and hospitalized between 2010 and 2011 at the Polish
Mother’s Memorial Hospital Research Institute (PMMHRI)
and at the Ludwig Rydygier Hospital in Lodz.
Materials and methods
The study included 1,250 randomly selected, newly regis-
tered pregnant women who attended the outpatient obstetric
clinics and were treated at the PMMHRI and the Ludwig
Rydygier Hospital between April, 2010 and March, 2011.
The cohort, hospitalized at the PMMHRI, consisted of
pregnant women from the Lodz Province and from other
Polish regions, as the PMMHRI houses a reference perinatal
care center.
Serological tests
Blood samples were obtained from pregnant women twice
during pregnancy (at the 12th–15th and the 30th–34th gesta-
tional weeks) and within a day from childbirth. Blood speci-
mens of 2.6 ml were collected from participants, who signed
an informed consent form. The blood was collected into
sterile, nonanticoagulated tubes. The collected samples were
centrifuged at 3,000 × g for 10 min and serum fractions were
stored at −20 °C.
Serum anti-HCMV IgG and IgM antibody levels were
assayed by enzyme-linked immunosorbent assay (ELISA)
tests (LIAISON®, DiaSorin, Italy), and seropositivity was
determined, using the manufacturer’s guidelines. The screen-
ing was performed using a LIAISON® immunoassay analyz-
er. All samples were considered as IgG- or IgM-positive when
the antibody levels were >0.4 IU/ml and >30 AU/ml, respec-
tively. For IgG avidity assessment, the indexes <0.300 were
interpreted as low avidity suggesting recent infection, whereas
the indexes ≥0.300 were interpreted as high avidity. Pregnant
women were considered as probably recently infected in cases
where specific IgG were elevated, IgM were present, and IgG
avidity was low. The kinetics of the specific antibodies was of
great importance. In those women, the presence of HCMV
DNAwas checked using a real-time Q PCR assay for the viral
UL55 gene in blood, urine, and amniotic fluid specimens [4].
DNA isolation and real-time Q PCR were carried out at the
Laboratory of Molecular Virology and Biological Chemistry,
Institute of Medical Biology, Polish Academy of Sciences in
Lodz.
All participants completed a structured questionnaire, in-
cluding data on the demographic and socioeconomic status, as
well as previous exposure to blood transfusion. The pregnant
women subjectively classified their financial status into one of
four categories: bad, average, good, and very good. The study
had been approved by the Ethical Committee of the PMMHRI
in Lodz and all the women participating in the study signed
the consent form.
Statistical analysis
The seroprevalence rates of anti-HCMV IgG and IgM anti-
bodies were assessed by means of descriptive statistics.
Relationships were determined between the prevalence rates
of HCMVand various socioeconomic factors, including age,
level of education, offspring, financial status, and a risk of
occupational contact with children and transfusions, using
cross-tabulation and Pearson’s Chi-squared test. Yates’ conti-
nuity correction for the Chi-squared test was used to deter-
mine differences in the risk of HCMV infections between
pregnant women with and without children at home.
Fisher’s exact test for count data was used to determine the
significance of the differences in HCMV IgM prevalence rates
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among pregnant women with different socioeconomic status.
For all socioeconomic factors, the prevalence rates and risk
ratios (PRs and RRs, respectively) of HCMV IgG were
assessed, using a binary logistic regression model. All results
were determined as being statistically significant at the signif-
icance level of p≤0.05. Data were analyzed using the Stata
v.11 software (StataCorp, College Station, TX, USA).
Results
Prevalence of IgG antibodies in different age groups
The study cohort consisted of 1,250 pregnant women, aged
16–45 years, among whom 62.4 % (780/1,250) were deter-
mined as HCMV IgG seropositive (see Table 1). The total
population of women was grouped into five age classes. The
prevalence rate was significantly associatedwith the age of the
patients (p=0.0069), with the highest value of 76.2 % (99/
130) observed in pregnant women aged ≥36 years, and the
lowest prevalence rate of 58.5 % (298/509) in women aged
26–30 years. A slightly higher prevalence rate of 66.0 % (33/
50) was found in patients aged 16–20 years. A significant
association between HCMV prevalence and age was observed
among pregnant women above 36 years of age [PR=1.89;
95 % confidence interval (CI) 1.17–3.07].
IgG prevalence in various socioeconomic groups
The study population was classified into three groups, accord-
ing to the education level (see Table 1). Appropriate data were
obtained for 1,180 pregnant women. Higher education was
recorded in 56.5 % (667/1,180) of women, secondary educa-
tion in 31.3 % (369/1,180), and primary and vocational edu-
cation was reported by 12.2 % (144/1,180). The HCMV
prevalence rate differed significantly among particular groups
with various education levels (p=0.0017). The prevalence rate
decreased with increasing education level, ranging from
72.9 % (105/144) in the group with primary and vocational
education to 58.0 % (387/667) in the group with university
education. A significant association with the prevalence rate
of infection was observed for secondary, primary, and voca-
tional education (PR=1.34; 95 % CI 1.00–1.79 and PR=1.80;
95 % CI 1.14–2.83, respectively).
The group of 1,170 pregnant women was also described in
relation to offspring in the household (see Table 1). In the
study population, 40.9 % (479/1,170) of pregnant women had
children. The prevalence rate differed significantly among the
groups of patients with and without children (p≤0.0001). The
differences stayed significant after Yates’ continuity correc-
tion. In women with offspring, the prevalence rate of infection
was 1.56 times higher than in those without children: 69.5 %
(333/479) vs. 57.3 % (396/691) (95 % CI 1.19–2.05;
p=0.0012). Additionally, the cohort was evaluated according
to the financial status and risk of occupational contact with
children, which was characteristic for professional groups,
such as school teachers, health care workers, social and com-
munity workers, as well as sales staff. Neither the financial
status nor the occupational contact with children and blood
transfusions influenced the prevalence rate (p=0.5115,
p=0.4843, and p=0.4247, respectively; see Table 1).
Considering the financial status, the highest prevalence of
infection was observed among the pregnant women with
average or good financial status (63.5 %), and the lowest
prevalence rate among women with the best financial status
(53.9 %). The prevalence rate among patients with or without
the occupational risk related to contact with children was
63.3 % (236/373) and 61.5 % (491/799), respectively.
Pregnant women with or without blood transfusions in their
history had prevalence rates of 56.5 % (26/46) and 62.3 %
(707/1,134), respectively. However, the observed differences
were not significant.
Out of the various socioeconomic factors, the level of
education and offspring in the household were determined as
being significantly associated with HCMV infection rates
(p=0.0276 and p=0.0016, respectively). The highest risk of
infection was observed in pregnant women with primary and
vocational education (RR 1.20, 95 % CI 1.05–1.37). A slight-
ly lower (1.17) RR (95 % CI 1.06–1.29) was found in women
with offspring. The age of pregnant women, their financial
status, the risk of occupational contact with children, and
blood transfusions in their history were not associated with
HCMV infections (p=0.0910, p=0.3469, p=0.6520, and
p=0.2004, respectively). However, the age of pregnant wom-
en tended to be an important risk factor of HCMV infections,
with the highest RR observed in patients above 36 years of age
(1.20, 95 % CI 1.06–1.36).
Prevalence of IgM antibodies
The prevalence of IgM antibodies was 2.2 % (28/1,250; see
Table 2) and, similarly to IgG, it was significantly associated
with the patients’ age (p=0.0174). The highest prevalence rate
of 6.0 % (3/50) was observed in pregnant women at the age of
16–20 years, and a little lower (4.6 %) (6/130) in those aged
≥36 years. Similarly to IgG antibodies, the lowest prevalence
rate of 1.0 % (5/509) was found in the group aged 26–
30 years.
IgM prevalence in various socioeconomic groups
The prevalence of specific IgM in the study cohort reached
2.2 % and was independent of any of the analyzed socioeco-
nomic factors. According to the level of education, similar
prevalence rates (2.0 %) were observed (p=1.0000; see
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Table 2). The prevalence rate of about 2.0 % was not corre-
lated either with offspring or with the occupational risk of
contact with children (p=1.0000 and p=0.4529, respectively).
Taking into account the financial status, the prevalence rate of
IgM varied from 1.4 to 2.6 % between classes, but the differ-
ences were not significant (p=0.6863). Pregnant women with
transfusions in their history presented with slightly higher
prevalence rates than those without such events, but the rela-
tionship was non-significant [4.3 % (2/46) vs. 2.0 % (23/
1,134); p=0.2544)].
Discussion
The seroprevalence of anti-HCMV IgG antibodies differs
throughout the world, ranging from 40 to 100 % [7, 17, 18].
The highest prevalence rates were reported in South America,
Africa, and Asia [6, 20]. In Europe, the lowest prevalence
rates were shown for pregnant women in the Netherlands
(41 %), followed by France (46 %) and the United Kingdom
(49 %) [27–29]. Higher prevalence rates were observed in
Belgium and Finland (50–60 %) [30, 31]. In the reported
study, we observed a prevalence rate of 62.4 % in the cohort
of 1,250 pregnant women. Given the prevalence rate of
76.7 % observed in Polish pregnant women hospitalized at
the same department in the earlier period between 1999 and
2009, the current data revealed a decrease in the HCMV
prevalence rate in the recent years [3], being similar to that
for pregnant women in Spain (57 %), Norway (60 %), and
Italy (68 %). Due to that reason, Poland can be placed among
the European countries with moderate prevalence rates [17,
32, 33]. Higher prevalence values were observed in Turkey,
ranging from 94.9% in the South to 96.4% in the North of the
country [18, 34].
Evaluating the age of pregnant women in our study cohort,
age above 36 years was the most important factor (PR=1.89)
associated with HCMV prevalence. A significantly higher
prevalence rate was observed in women above 36 years old
than in younger ones, aged 26–30 years (76.2 vs. 58.5 %).
Similarly, higher prevalence rates for older pregnant women
were observed in the British Isles, Italy, India, and Australia
[23, 25, 26, 35].
In our study, the age of pregnant women also tended to be a
risk factor of HCMV infections, with the highest risk ratio
(RR=1.20) observed in women older than 36 years. The lack
of statistical significance for the relationship between the age
of pregnant women and the prevalence rate of infection pos-
sibly resulted from the relatively small number of pregnant
women above 36 years of age, compared to the number of
women aged 26–30 and 31–35 years. By contrast, the reports
from studies on Northern Italian pregnant women have indi-
cated no association between HCMV prevalence and patient
age [17], which might have resulted from the low number of
pregnant women in the youngest and oldest study groups (1.7
and 3.2 % of the study cohort, respectively) [17]. In our study
cohort, the prevalence rate in the youngest pregnant women
aged 16–20 and 21–25 years was higher than that observed
among women aged 26–30 years (66.0 and 61.3% vs. 58.5%,
respectively). One possible explanation for the relatively high
prevalence, observed in the youngest groups, could refer to
the small number (4.0 and 15.9 % of the whole cohort,
respectively). However, the young age of pregnant women
below 25 years of age, also reported in other studies, seems to
be an important reason as well [22, 28].
Beside the region and age, other socioeconomic risk factors
for HCMV infections have also been reported [21, 24, 36].
Higher prevalence rates in correlation with lower socioeco-
nomic status were determined in pregnant women from
Finland (60.9 vs. 76.4 %) and India (63.4 vs. 96.9 %) [24,
25]. A significant influence of this factor on the prevalence
rates of the infection was also observed in the British Isles and
Italy [23, 26]. In our study cohort, we estimated a significant
influence of the education level on the HCMV prevalence
rate. The highest prevalence and risk of HCMVinfection were
characteristic for pregnant women with primary and vocation-
al education (72.9 % vs. 64.5 and 58.0 % for primary and
vocational vs. secondary and higher education, respectively;
Table 2 HCMV IgM prevalence and risk factors in the studied cohort of
pregnant women
Risk factors Classes HCMV IgM
positive (%)
Total 28 (2.2 %)
Age ≤20 3 (6.0 %)
21–25 4 (2.0 %)
26–30 5 (1.0 %)
31–35 10 (2.8 %)
≥36 6 (4.6 %)
Education Higher 14 (2.1 %)
Secondary 7 (1.9 %)
Primary and vocational 3 (2.1 %)
Having children No 15 (2.2 %)
Yes 10 (2.1 %)
Financial status Bad 1 (2.1 %)
Average 5 (1.4 %)
Good 16 (2.6 %)
Very good 2 (2.6 %)
Unknown 4 (2.6 %)
Risk of occupational
contact with children
No 16 (2.0 %)
Yes 9 (2.4 %)
Transfusions No 23 (2.0 %)
Yes 2 (4.3 %)
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PR=1.80, RR=1.20). A slightly lower influence on the prev-
alence rate of HCMV infection was observed for women with
secondary education (PR=1.56). Since no other study has yet
been performed to investigate the relationships between edu-
cation level and the prevalence of HCMV, further research on
the role of education as a risk factor of HCMV infections in
pregnant women seems to be challenging and necessary.
HCMV prevalence among pregnant women might also be
affected by having children [21, 25, 28]. In our study, we
observed a significantly higher prevalence of HCMVinfection
in pregnant women with offspring than in those without
children (69.5 % vs. 57.3; PR=1.56). It is consistent with
the differences in the prevalence rates reported for pregnant
women from India (96.0, 93.1, and 66.7 % for women having
≥3, 1–2, and no children, respectively) and the British Isles
(from 66.2 to 46.4 % vs. 38.9 % for women having 4–1 vs.
those without children, respectively) [25, 26, 36]. In addition,
our study also showed having children as a significant risk
factor of HCMV infections during pregnancy (RR=1.17).
Considering the financial status, we noticed the lowest
HCMV prevalence among women with the best status (53.9
vs. 58.3 % in women with very good vs. bad status, respec-
tively). Fairly similar HCMV IgG seroprevalences were ob-
served among pregnant women in Norway, where low family
income was associated with higher CMV IgG seropositivity
compared to high family incomes [62.9 vs. 53.8 %; odds ratio
(OR)=1.46, 95 % CI 1.00 to 2.12] [32]. However, in our
study, the highest prevalence of HCMV infection was ob-
served in pregnant women with good and average financial
status (63.5%), whichmay suggest the lack of influence of the
economic status on HCMV infections in our cohort.
In the reported study, we also analyzed the occupational
contact with children and blood transfusions as possible risk
factors of HCMV infections. However, none of them was
associated with HCMV prevalence rate. So far, the previously
reported results related to the influence of occupational con-
tact with children on HCMV prevalence rates were contrary to
our observations [21, 37–40]. Based on those studies, we
suggest that occupational contact with children is a
population-dependent risk of HCMVinfections. The observed
discrepancies might originate from other factors, including
hygiene behaviors and the age of children, cared for by the
pregnant women included in the study [37, 41]. Accordingly
to the role of transfusions in HCMVinfections, we indicated a
lack of any association between these factors investigated in
our pregnancy cohort. This is similar to the relationship
showed for multitransfused patients from Bangladesh [42].
No other papers have focused on transfusions as a risk factor
of HCMV infections, although studies on HCMV prevalence
among blood donors have been performed [43–45].
In this paper, we also analyzed the seroprevalence of anti-
HCMV IgM antibodies. In the studied cohort, the IgM prev-
alence rate was 2.2 %. Similar prevalence rates were also
reported for pregnant women in Finland (4.0 %), Australia
(5.5 %), and France (5.7 %) [24, 27, 35]. In the case of the
French cohort, the IgM prevalence rate of 5.7 % was charac-
teristic for HCMV-IgG seropositive women, while for the
whole study cohort, the IgM prevalence rate was 2.7 %, being
similar to the prevalence observed among Polish pregnant
women [27]. In addition, both our and French serological
screenings were performed by means of the same laborato-
ry tests [27]. In our study, we observed a significant asso-
ciation of the IgM prevalence with patient age, with chang-
es in age-stratified prevalence rates similar to those ob-
served for IgG antibodies. However, no current studies
showed any association between age and the HCMV IgM
prevalence rates [39, 40, 46]. We suggest that the relatively
low IgM prevalence rates, reported in various populations,
may have been responsible for the observed discrepancies.
In the population of US pregnant women aged 12–49 years,
the IgM prevalence rate was 3.0 %, but stayed relatively flat
across the age groups [46]. Despite the fact that, in our
cohort, age-associated differences in the IgM prevalence
rates were observed, the lack of a significant age-related
trend was fairly distinctive [46].
Similarly to other studies, no associations were found
between the IgM prevalence rates and other risk factors,
including education level, offspring, financial status, and the
occupational risk of contact with children [24, 27, 47]. We
suggest that the lack of relationships might be possibly caused
by the relatively low seroprevalence of IgM in the study
population (2.2 %; 28/1,250). It seems plausible that only a
large cohort study might show the risk factors influencing the
prevalence rate of the IgM antibodies. The IgM prevalence
tended to be higher in pregnant women with transfusions in
their history than in those without transfusion events (4.3
vs. 2.0 %). The lack of significance in the relationship
observed in our study might have resulted from the small
number of transfused women (3.9 %, 46/1,180). In
Bangladesh, a significant increase was observed in the
seroprevalence of IgM antibodies for multitransfused pa-
tients, showing transfusions as a possible risk factor of
HCMV infections during pregnancy [42].
In comparison with other European pregnancy populations,
the prevalence of IgG anti-HCMV in the Polish pregnancy
cohort is high. Primary and vocational education, having
children, and age above 36 years are most serious risk factors
of HCMV infections during pregnancy. This indicates the
primary prophylaxis to increase the awareness of the risks,
related to HCMV infections, in pregnancy as an extremely
important measure.
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